Dementia development risk in maturi ty patients with type 2 di abetes mellitus depending on the existing complications and methods of its correction
Pdf (Українська)

Keywords

diabetes, depression, dementia, forecast, alpha lipoic acid, pregabalin

How to Cite

Zherdova, N. (2017). Dementia development risk in maturi ty patients with type 2 di abetes mellitus depending on the existing complications and methods of its correction. Endokrynologia, 22(2), 102-107. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/65

Abstract

Diabetes, dementia, chronic diseases that lead to complications and disability in patients. Timely detection of risk factors that lead to the development of diabetes complications, including the development of dementia, and to find opportunities to reduce their impact, will help reduce the disability population. The aim of the study was to calculate the 10-year forecast for the development of dementia in patients with type 2 diabetes adulthood. Materials and methods. 81 patients were examined with type 2 diabetes aged 45 to 59 years, of which 43 people were women and 38 — men. Patients were divided into groups: diagnosed with diabetic retinopathy and without it, with and without hypoglycemia, depressive disorders with or without them. In order to identify depression questionnaire used Centre for Epidemiologic Studies Depression Scale (CES-D). In the group with diabetic  etinopathy
include patients with 2-4 stages. Diabetic neuropathy was diagnosed by means of a graduated tuning fork. Prediction dementia risk was performed using a 10-year scale prediction of dementia. Results. Forecast risk of dementia in patients with type 2 diabetes adulthood with hypoglycemia 1.8 times worse than patients without hypoglycemia, depression — In 1.82 times compared with those without depression, with DR compared to 1.39 with a group of persons without DR. Conclusion. Carrying out of pathogenetic therapy of diabetic neuropathy, Dialipon (alpha-lipoic acid) and the possibility of adding Ograniya (pregabalin) to reduce not only the manifestations of painful neuropathy, but also reduced the
manifestations of depression.

Pdf (Українська)

References

1. www.IDF.org.
2. www.worldalzreport2015.org
3. Palta P., Schneider A.L., Biessels G.J., Touradji P., Hill-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains // J. Int. Neuropsychol. Soc. — 2014. — Vol. 20. — P. 278-291.
4. Van den Berg E., Kloppenborg R.P., Kessels R.P., Kappelle L.J., Biessels G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition // Biochim. Biophys. Acta. — 2009. — Vol. 1792, № 5. — P. 470-481.
5. Crichton G.E., Elias M.F., Buckley J.D., Murphy K.J., Bryan J., Frisardi V. Metabolic syndrome, cognitive performance, and dementia // J. Alzheimers Dis. — 2012. — Vol. 30, Suppl. 2. — P. 77-87.
6. Lamport D.J., Lawton C.L., Mansfi eld M.W., Dye L. Impairments in glucose tolerance can have a negative impact on cognitive function: a systematic research review // Neurosci. Biobehav.
Rev. — 2009. — Vol. 33. — P. 394-413.
7. Ruis C., Biessels G.J., Gorter K.J., van den Donk M., Kappelle L.J., Rutten G.E. Cognition in the early stage of type 2 diabetes // Diabetes Care. — 2009. — Vol. 32. — P. 1261-1265.
8. Euser S.M., Sattar N., Witteman J. C.M., Bollen E.L.E.M., Sijbrands E.J.G., Hofman A., Perry I.J., Breteler M.M.B., Westendorp R.G.J., and for PROSPER and the Rotterdam Study. A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. — Diabetes. — 2010. — Vol. 59, № 7. — P. 1601-1607.
9. Van den Berg E., Reijmer Y.D., de Bresser J., Kessels R.P., Kappelle L.J., Biessels G.J. and the Utrecht Diabetic Encephalopathy Study Group. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus // Diabetologia. — 2010. — Vol. 53. — P. 58-65.
10. Yaffe K., Falvey C., Hamilton N., Schwartz A.V., Simonsick E.M., Satterfield S., Cauley J., Rosano C., Launer L., Strotmeyer E.S., Harris T. Diabetes, glucose control, and 9 year cognitive decline among non-demented older adults // Arch. Neurol. — 2012. — Vol. 69, № 9. — P. 1170-1775.
11. Cukierman-Yaffe T., Gerstein H.C., Williamson J.D., Lazar R.M., Lovato L., Miller M.E., Coker L.H., Murray A., Sullivan M.D., Marcovina S.M., Launer L.J. Relationship between baseline
glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk indiabetes-memory in diabetes (ACCORDMIND) trial // Diabetes Care. — 2009. — Vol. 32, № 2. — P. 221-226.
12. Whitmer R.A., Karter A.J., Yaffe K., Quesenberry C.P., Jr., Selby J. V. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus // JAMA. — 2009. — Vol. 301, № 15. — P. 1565-1572.
13. Bendtson I., Gade J., Theilgaard A., Binder C. Cognitive function in type 1 (insulin-dependent) diabetic patients after nocturnal hypoglycaemia // Diabetologia. — 1992. — Vol. 35, № 9. —
P. 898-903.

Downloads

Download data is not yet available.